Ćeriman Krstić Vesna, Gajić Milija, Djukanović Leonida, Jovanović Dragana
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Clinic for Pulmonology, University Clinical Center of Serbia, Belgrade, Serbia.
Front Drug Saf Regul. 2025 Apr 24;5:1528468. doi: 10.3389/fdsfr.2025.1528468. eCollection 2025.
Despite significant advances in lung cancer treatment, patients with this disease still present with multiple symptoms that are very hard to control. Corticosteroids are widely used in patients with lung cancer, but without clear evidence for their efficacy. Thus, corticosteroids have been used for the treatment of conditions arising due to the tumor itself, adverse effects of the applied specific therapy and symptom palliation. In this review we are going to summarize clinical indications for corticosteroid use in patients with lung cancer: malignant airway obstruction, superior vena cava syndrome, brain metastases, treatment-related adverse events, anorexia and cachexia, fatigue, dyspnea, nausea and vomiting, spinal cord compression, and pain.
尽管肺癌治疗取得了重大进展，但患有这种疾病的患者仍存在多种难以控制的症状。皮质类固醇广泛用于肺癌患者，但尚无明确证据证明其疗效。因此，皮质类固醇已被用于治疗因肿瘤本身、所应用的特定疗法的不良反应以及症状缓解而引起的病症。在本综述中，我们将总结肺癌患者使用皮质类固醇的临床指征：恶性气道阻塞、上腔静脉综合征、脑转移、治疗相关不良事件、厌食和恶病质、疲劳、呼吸困难、恶心和呕吐、脊髓压迫以及疼痛。
